Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.

Elderly haematologic cancer patients at risk of depression

06 Jun 2020

Depressive symptoms and low quality of life (QoL) are likely to occur in elderly patients with haematologic malignancies, a recent study has found.

Researchers conducted a prospective analysis of 200 elderly patients (mean age, 75.6±4.9 years; 64.0 percent male) with haematologic cancers. The Patient Health Questionnaire (PHQ-9) was used to evaluate depressive symptoms while the Generalized Anxiety Disorder (GAD) tool was used to evaluate anxiety symptoms. A parallel group of 225 healthy controls (mean age, 75.8±3.7 years; 59.6 percent male) was also included.

Overall depression was documented in 4.5 percent of cancer patients, as opposed to only 3.7 percent of community controls (p<0.001). In addition, moderate to severe depression had a prevalence of 16.5 percent and 9.1 percent in the respective groups. Anxiety, on the other hand, occurred at comparable rates between groups.

Patients also reported feeling more tired, having less appetite, having more sleep difficulties, and feeling slowed down relative to the community controls.

Hierarchical regression analysis revealed that ongoing chemotherapy, lack of partnership, and poor QoL were strong indicators of depression in elderly haematologic cancer patients, accounting for 67 percent of the total variability in depression. Role, emotional, cognitive, and social functioning were likewise important predictors, explaining 42 percent of the total variability.

“While we found several variables showing a strong association with depression, we cannot determine whether they are a cause or result of increased depressive symptoms,” said the researchers. “Longitudinal studies are needed to determine causality in levels of distress across diagnosis, treatment, and rehabilitation.”

“Gaining a clearer understanding of the trajectory of depression and anxiety as well as underlying cause-and-effect relations could greatly improve treatment and rehabilitation,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.